FDA Pipeline preview, December 2008 (denileukin, ferumoxytol, cetuximab, HQK-1001, ALD-101, NTX-010, RTA 402)

News
Article

Recent FDA action (through December 2008) related to denileukin, ferumoxytol, cetuximab, HQK-1001, ALD-101, NTX-010, and RTA 402

Complete responses

• Denileukin diftitox (Ontak, Eisai) for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells did not test positive for the CD25 component of the interleukin-2 receptor

•Controlled-release hydrocodone plus acetaminophen (Abbott) for the relief of pain over 12 hours

Priority review

•Cetuximab (Erbitux, ImClone/Bristol-Myers Squibb) for use in combination with platinum-based chemotherapy for the first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck

Orphan drug designations

•HQK-1001 (HemaQuest) for the treatment of sickle cell anemia and beta thalassemia

•ALD-101 (Aldagen) to decrease time to platelet and neutrophil engraftment in patients with inherited metabolic disorders undergoing umbilical cord blood transplantation

•NTX-010 (Neotropix) for the treatment of neuroendocrine tumors

•RTA 402 (Reata) for the treatment of pancreatic cancer

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.